Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 516Lymphoid 461Myeloid 179Plasma cell 136Dermatologic 80Gastrointestinal 71Gynecologic 56Genitourinary 47Classical hematology 42Thoracic 41Sarcoma 39Breast 39CNS 35Other solid neoplasm 32Head & Neck 29Tumor-Agnostic 8Other neoplasm 5Endocrine 3NET 2

Conditions

Sarcoma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Urogenital Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma 1Histiocytoma, Malignant Fibrous 1Giant Cell Tumor of Bone 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × fludarabine × Endocrine × Clear all
NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03935893 2025-07-10

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

University of Pittsburgh

Phase 2 Recruiting
240 enrolled
DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡